Autres langues Editas Medicine, Inc.

Actions

EDIT

US28106W1036

Temps réel estimé Cboe BZX Autres places de cotation 16:54:10 10/06/2024			Varia. 5j.	Varia. 1 janv.
5,165 ^USD	-2,55 %		-4,53 %	-49,01 %

30/05	EDITAS MEDICINE, INC. : Evercore ISI est neutre sur le titre	ZM
14/05	Un initié d'Editas Medicine a acheté des actions pour une valeur de 253 868 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing	14/05
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June	14/05
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June	14/05
Editas Medicine Preclinical Data Highlights Advancement Of In Vivo Gene Editing Medicine Technologies at The American Society Of Gene And Cell Therapy Annual Meeting	13/05
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting	10/05
Editas: Q1 Earnings Snapshot	08/05
Editas Medicine Announces First Quarter 2024 Results and Business Updates	08/05
Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events	02/05
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	01/05
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	01/05
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	01/05
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting	22/04
Editas Medicine : April 2024 Corporate Presentation	12/04
Editas Medicine : Corporate Effectiveness Report April 2024	12/04
Editas: Q4 Earnings Snapshot	28/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02
Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Editas Medicine, Inc.

Actions

EDIT

US28106W1036

Autres langues

Filtres